secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2026-07-15T21:36:30+00:00
Accession:  0001193125-26-304984
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharmaceuticals completes merger with Angelini Pharma; shareholders receive $31.50/share
--------------------------------------------------------------------------------

- Merger closed July 15, 2026; each share converted to $31.50 cash, no interest.
- Stock to be delisted from Nasdaq; trading suspended July 16, 2026.
- All directors resigned; new directors from Angelini (Sergio Marullo di Condojanni, Massimo Marin, Enrica Dogali) appointed.
- Certificate of incorporation and bylaws amended and restated.
- Company becomes wholly owned subsidiary of Angelini Pharma S.p.A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/0001193125-26-304984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/d159184d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-304984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer